<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        450-212-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CROTAL 1MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TACROLIMUS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        423.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AD02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CROTAL<sup>&reg;</sup>&nbsp;belongs to a group of medicines called immunosuppressants. Following your organ transplant (e.g. liver, kidney, heart), your body&rsquo;s immune system will try to reject the new organ.</p><p>CROTAL<sup>&reg;</sup>&nbsp;is used to control your body&rsquo;s immune response enabling your body to accept the transplanted organ.</p><p>CROTAL<sup>&reg;</sup>&nbsp;is often used in combination with other medicines that also suppress the immune system.</p><p>You may also be given CROTAL<sup>&reg;</sup>&nbsp;for an ongoing rejection of your transplanted liver, kidney, heart or other organ or if any previous treatment you were taking was unable to control this immune response after your transplantation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take CROTAL<sup>&reg;</sup></strong></p><ul><li>If you are allergic (hypersensitive) to tacrolimus or any of the other ingredients of CROTAL<sup>&reg;</sup>&nbsp;(listed in section 6).</li><li>If you are allergic (hypersensitive) to any antibiotic belonging to the subgroup of macrolide antibiotics (e.g. erythromycin, clarithromycin, josamycin).</li></ul><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking CROTAL<sup>&reg;</sup></p><ul><li>You will need to take CROTAL<sup>&reg;</sup>&nbsp;every day as long as you need immunosuppression to prevent rejection of your transplanted organ. You should keep in regular contact with your doctor.</li><li>Whilst you are taking CROTAL<sup>&reg;</sup>&nbsp;your doctor may want to carry out a number of tests (including blood, urine, heart function, visual and neurological tests) from time to time. This is quite normal and will help your doctor to decide on the most appropriate dose of CROTAL<sup>&reg;</sup>&nbsp;for you.</li><li>Please avoid taking any herbal remedies, e.g. St. John&rsquo;s wort (Hypericum perforatum) or any other herbal products as this may affect the effectiveness and the dose of CROTAL<sup>&reg;</sup>&nbsp;that you need to receive. If in doubt please consult your doctor prior to taking any herbal products or remedies.</li><li>If you have liver problems or have had a disease which may have affected your liver, please tell your doctor as this may affect the dose of CROTAL<sup>&reg;</sup>&nbsp;that you receive.</li><li>If you feel strong abdominal pain accompanied or not with other symptoms, such as chills, fever, nausea or vomiting.</li><li>If you have diarrhoea for more than one day, please tell your doctor, because it might be necessary to adapt the dose of CROTAL<sup>&reg;</sup>&nbsp;that you receive.</li><li>If you have an alteration of the electrical activity of your heart called &ldquo;QT prolongation&rdquo;.</li><li>Limit your exposure to sunlight and UV light whilst taking CROTAL<sup>&reg;</sup>&nbsp;by wearing appropriate protective clothing and using a sunscreen with a high sun protection factor. This is because of the potential risk of malignant skin changes with immunosuppressive therapy.</li><li>If you need to have any vaccinations, please inform your doctor beforehand. Your doctor will advise you on the best course of action.</li><li>Patients treated with CROTAL<sup>&reg;</sup>&nbsp;have been reported to have an increased risk of developing lymphoproliferative disorders (see section 4). Ask your doctor for specific advice on these disorders.</li></ul><p><strong>Other medicines and CROTAL<sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription and herbal remedies.</p><p>CROTAL<sup>&reg;</sup>&nbsp;must not be taken with ciclosporin.</p><p>CROTAL<sup>&reg;</sup>&nbsp;blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking CROTAL<sup>&reg;</sup>&nbsp;which may require interruption, an increase or a decrease in CROTAL<sup>&reg;</sup>&nbsp;dose. In particular, you should tell your doctor if you are taking or have recently taken medicines with active substances like:</p><ul><li>antifungal medicines and antibiotics (particularly so-called macrolide antibiotics) used to treat infections e.g. ketoconazole, fluconazole, itraconazole, voriconazole, clotrimazole, erythromycin, clarithromycin, josamycin, and rifampicin</li><li>HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir), used to treat HIV infection</li><li>HCV protease inhibitors (e.g. telaprevir, boceprevir), used to treat hepatitis C infection</li><li>medicines for stomach ulcer and acid reflux (e.g. omeprazole, lansoprazole or cimetidine)</li><li>antiemetics, used to treat nausea and vomiting (e.g. metoclopramide)</li><li>magnesium-aluminium-hydroxide (antacid), used to treat heartburn</li><li>hormone treatments with ethinylestradiol (e.g. the oral contraceptive pill) or danazol</li><li>medicines for high blood pressure or heart problems such as nifedipine, nicardipine, diltiazem and verapamil</li><li>anti-arrhythmic medicines (amiodarone) used to control arrhythmia (uneven beating of the heart)</li><li>medicines known as &ldquo;statins&rdquo; used to treat elevated cholesterol and triglycerides</li><li>the anti-epileptic medicines phenytoin or phenobarbital</li><li>the corticosteroids prednisolone and methylprednisolone</li><li>the anti-depressant nefazodone</li><li>herbal preparations containing St. John&#39;s Wort (<em>Hypericum perforatum</em>) or extracts of&nbsp;<em>Schisandra sphenanthera.</em></li></ul><p>Tell your doctor if you are taking or need to take ibuprofen, amphotericin B, or antivirals (e.g. aciclovir). These may worsen kidney or nervous system problems when taken together with CROTAL<sup>&reg;</sup>.</p><p>Your doctor also needs to know if you are taking potassium supplements or potassium-sparing diuretics (e.g., amiloride, triamterene, or spironolactone), certain pain killers (so-called NSAIDs, e.g. ibuprofen), anticoagulants, or oral medication for diabetic treatment, while you take CROTAL<sup>&reg;</sup>.</p><p>If you need to have any vaccinations, please inform your doctor beforehand.</p><p><strong>CROTAL<sup>&reg;</sup>&nbsp;with food and drink</strong></p><p>You should generally take CROTAL<sup>&reg;</sup>&nbsp;on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. Grapefruit and grapefruit juice should be avoided while taking CROTAL<sup>&reg;</sup>.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>CROTAL<sup>&reg;</sup>&nbsp;is excreted into breast milk. Therefore you should not breast-feed whilst receiving CROTAL<sup>&reg;</sup>.</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking CROTAL<sup>&reg;</sup>. These effects are more frequently observed if CROTAL<sup>&reg;</sup>&nbsp;is taken in conjunction with alcohol use.</p><p><strong>CROTAL<sup>&reg;</sup>&nbsp;contains lactose </strong></p><p>CROTAL<sup>&reg;</sup>&nbsp;contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take CROTAL<sup>&reg;</sup>&nbsp;exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Make sure that you receive the same tacrolimus medicine every time you collect your prescription, unless your transplant specialist has agreed to change to a different tacrolimus medicine.</p><p>This medicine should be taken twice a day. If the appearance of this medicine is not the same as usual, or if dosage instructions have changed, speak to your doctor or pharmacist as soon as possible to make sure that you have the right medicine.</p><p>The starting dose to prevent the rejection of your transplanted organ will be determined by your doctor calculated according to your body weight. Initial doses just after transplantation will generally be in the range of 0.075 &ndash; 0.30 mg per kg body weight per day depending on the transplanted organ.</p><p>Your dose depends on your general condition and on which other immunosuppressive medication you are taking. Regular blood tests by your doctor will be required to define the correct dose and to adjust the dose from time to time. Your doctor will usually reduce your CROTAL<sup>&reg;</sup>&nbsp;dose once your condition has stabilised. Your doctor will tell you exactly how many capsules to take and how often.</p><p>CROTAL<sup>&reg;</sup>&nbsp;is taken orally twice daily, usually in the morning and evening. You should generally take CROTAL<sup>&reg;</sup>&nbsp;on an empty stomach or at least 1 hour before or 2 to 3 hours after the meal. The capsules should be swallowed whole with a glass of water. Take the capsules immediately following removal from the blister. Avoid grapefruit and grapefruit juice while taking CROTAL<sup>&reg;</sup>.</p><p><strong>If you take more CROTAL<sup>&reg;</sup>&nbsp;than you should</strong></p><p>If you have accidentally taken too much CROTAL<sup>&reg;</sup>&nbsp;see your doctor or contact your nearest hospital emergency department immediately.</p><p><strong>If you forget to take CROTAL<sup>&reg;</sup></strong></p><p>Do not take a double dose to make up for forgotten individual doses.</p><p>If you have forgotten to take your CROTAL<sup>&reg;</sup>&nbsp;capsules, wait until it is time for the next dose, and then continue as before.</p><p><strong>If you stop taking CROTAL<sup>&reg;</sup></strong></p><p>Stopping your treatment with CROTAL<sup>&reg;</sup>&nbsp;may increase the risk of rejection of your transplanted organ. Do not stop your treatment unless your doctor tells you to do so.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep&nbsp;out of the reach and sight of children.</p><p>Take the capsules immediately following removal from the Blister.</p><p>Do not use CROTAL<sup>&reg;</sup>&nbsp;after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep&nbsp;out of the reach and sight of children.</p><p>Take the capsules immediately following removal from the Blister.</p><p>Do not use CROTAL<sup>&reg;</sup>&nbsp;after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CROTAL<sup>&reg;</sup>&nbsp;0.5 mg capsules</p><ul><li>The active substance is tacrolimus. Each capsule contains 0.5 mg of tacrolimus as tacrolimus PreMix.</li><li>The other ingredients are:<br />Capsule content: croscarmellose sodium, lactose monohydrate, magnesium stearate.</li><li>Capsule shell: Red ink, gelatin.</li></ul><p>CROTAL<sup>&reg;</sup>&nbsp;1 mg capsules</p><ul><li>The active substance is tacrolimus. Each capsule contains 1 mg of tacrolimus as tacrolimus PreMix.</li><li>The other ingredients are:<br />Capsule content: croscarmellose sodium, lactose monohydrate, magnesium stearate.<br />Capsule shell: Red ink, gelatin.</li></ul><p>CROTAL<sup>&reg;</sup>&nbsp;5 mg capsules</p><ul><li>The active substance is tacrolimus. Each capsule contains 5 mg of tacrolimus as tacrolimus PreMix.</li><li>The other ingredients are:<br />Capsule content: croscarmellose sodium, lactose monohydrate, magnesium stearate.<br />Capsule shell: White ink, gelatin.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CROTAL® 0.5 mg capsules
Size “4” empty hard gelatin capsule shell with dark yellow opaque cap imprinted with “0.5 MG” and dark yellow opaque body imprinted with “RDY 525” using red ink.
CROTAL® 1 mg capsules
Size "4" empty hard gelatin capsule shell with white opaque cap imprinted with "1MG" and white opaque body imprinted with "RDY 526" using red ink 
CROTAL® 5 mg capsules
Size "4" empty hard gelatin capsule shell with dark greyish red opaque cap imprinted with "5MG" and dark greyish red opaque body imprinted with "RDY 527" using white ink.
All strength contains 100 Capsules/10 Blister/Unit Cartoon.
Each strip contains 10 capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by </strong></p><p>Dr. Reddy&#39;s Laboratories Limited</p><p><strong>FOR</strong></p><p>SPIMACO</p><p>Al-Qassim pharmaceutical plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2019.                       
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">كروتال&nbsp;<sup>&reg;</sup> ينتمي إلى مجموعة من الأدوية تسمى مثبطات المناعة.&nbsp;بعد عملية زرع الأعضاء (مثل الكبد والكلى والقلب)، سيحاول الجهاز المناعي للجسم رفض العضو الجديد.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup> يستخدم للسيطرة على استجابة جسمك المناعية مما يسمح لجسمك بقبول العضو المزروع.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup> غالبا ما يتم تناوله مع الأدوية الأخرى التي تقمع أيضا جهاز المناعة.</p><p dir="RTL">قد يتم وصف كروتال&nbsp;<sup> &reg;</sup> أيضا في حالة الرفض المستمر للكبد المزروع أو الكلى أو القلب أو أي عضو آخر أو إذا كان أي علاج سابق كنت تتناوله غير قادر على السيطرة على هذه الاستجابة المناعية بعد عملية الزرع .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول</strong>&nbsp;<strong>كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لديك حساسية (فرط الحساسية)&nbsp;لتاكروليموس&nbsp;أو أي من المكونات الأخرى في&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;&nbsp;&nbsp;(المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لديك حساسية (فرط الحساسية) إلى أي مضاد حيوي ينتمي إلى المجموعة الفرعية من&nbsp;المضادات الحيوية&nbsp;ماكروليد&nbsp;(على سبيل المثال الاريثروميسين،&nbsp;كلاريثروميسين&nbsp;،&nbsp;جوساميسين&nbsp;).</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف تحتاج إلى تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;&nbsp;&nbsp;كل يوم طالما كنت في حاجة&nbsp;إلى&nbsp;تثبيط المناعة&nbsp;لمنع رفض العضو المزروع الخاص بك.&nbsp;يجب أن تبقى على اتصال منتظم مع طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;&nbsp;&nbsp;قد يرغب طبيبك في إجراء عدد من الاختبارات (بما في ذلك الدم والبول ووظيفة القلب والاختبارات البصرية والعصبية) من وقت لآخر.&nbsp;هذا أمر طبيعي جدا وسوف يساعد طبيبك لاتخاذ قرار بشأن الجرعة الأنسب من&nbsp;كروتال&nbsp;<sup>&reg;</sup>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى تجنب تناول أي علاجات عشبية، مثل&nbsp;نبتة&nbsp;سانت جون&nbsp;(&nbsp;هيبيريكوم&nbsp;بيرفوراتوم&nbsp;) أو أي من المنتجات العشبية الأخرى لأن هذا قد يؤثر على فعالية و جرعة كروتال&nbsp;<sup>&reg;</sup>&nbsp;التي تحتاج إلى تناولها. إذا كنت في شك يرجى استشارة الطبيب قبل تناول أي منتجات أو علاجات عشبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكبد أو كان لديك مرض قد يكون أثر على الكبد، يرجى إخبار طبيبك لأن هذا قد يؤثر على جرعة كروتال&nbsp;<sup>&reg;</sup>&nbsp;التي تتلقاها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشعر بألم بطني قوي مصحوب أو لا مع أعراض أخرى، مثل قشعريرة، حمى، غثيان أو قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك إسهال لأكثر من يوم واحد، من فضلك أخبر طبيبك، لأنه قد يكون من الضروري تعديل جرعة كروتال&nbsp;<sup>&reg;</sup>&nbsp;التي تتلقاها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تغيير في النشاط الكهربائي القلبي يسمى &quot;تطويل فترة QT&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من التعرض لأشعة الشمس والأشعة فوق البنفسجية أثناء تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;من خلال ارتداء الملابس الواقية المناسبة واستخدام واقيات من الشمس مع عامل الحماية من أشعة الشمس العالية.&nbsp;هذا بسبب المخاطر المحتملة للتغيرات الجلد الخبيثة مع العلاجات المثبطة للمناعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى أي لقاحات، يرجى إبلاغ الطبيب مسبقا.&nbsp;سيقوم طبيبك بإرشادك بشأن أفضل طريقة لتلقي اللقاح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين تناولوا كروتال&nbsp;<sup>&reg;</sup>&nbsp;قد تم الإبلاغ عن أن لديهم خطر متزايد من حدوث&nbsp;اضطرابات&nbsp;لمفاوية&nbsp;(انظر القسم 4).اسأل طبيبك حول هذه الاضطرابات.</p><p dir="RTL"><strong>أدوية أخرى و</strong> <strong>كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية والعلاجات العشبية.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup>&nbsp;يجب ألا يتم تناوله مع السيكلوسبورين.</p><p dir="RTL">مستويات كروتال&nbsp;<sup>&reg;</sup>&nbsp; في الدم يمكن أن تتأثر بالأدوية الأخرى التي تتناولها، ومستويات الأدوية الأخرى في الدم يمكن أن تتأثر بتناول&nbsp;كروتال&nbsp;<sup>&reg;</sup> والتي قد تتطلب وقف، زيادة أو نقصان جرعة&nbsp;كروتال&nbsp;<sup>&reg;</sup>.&nbsp;على وجه الخصوص، يجب أن تخبر طبيبك إذا كنت تتناول أو قد تناولت مؤخرا الأدوية التي تحتوي على المواد الفعالة الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للفطريات والمضادات حيوية (خاصة ما يسمى&nbsp;المضادات الحيوية من مجموعة&nbsp;ماكرولايد)&nbsp;التي تستخدم لعلاج العدوى مثل&nbsp;الكيتوكونازول ،&nbsp;الفلوكونازول ،&nbsp;ايتراكونازول،&nbsp;فوريكونازول ،&nbsp;كلوتريمازول ،&nbsp;الاريثروميسين ،&nbsp;كلاريثروميسين ،&nbsp;جوساميسين ، &nbsp;والريفامبيسين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إنزيم البروتيز الخاص بفيروس نقص المناعة البشرية (مثل&nbsp;ريتونافير&nbsp;،&nbsp;نلفينافير&nbsp;،&nbsp;ساكينافير&nbsp;)، وتستخدم لعلاج عدوى فيروس نقص المناعة البشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أنزيم البروتيز الخاصة بفيروس الالتهاب الكبدي سي (مثل&nbsp;تيلابريفير&nbsp;،&nbsp;بوسبريفير&nbsp;)، وتستخدم لعلاج فيروس التهاب الكبد سي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لقرحة المعدة وارتداد الحمض (مثل&nbsp;أوميبرازول&nbsp;،&nbsp;لانسوبرازول&nbsp;أو&nbsp;سيميتيدين&nbsp;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات القيء&nbsp;، وتستخدم لعلاج الغثيان والقيء (على سبيل المثال&nbsp;ميتوكلوبراميد&nbsp;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكسيد المغنيسيوم والألمونيوم (مضاد للحموضة)، وتستخدم لعلاج حرقة المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج الهرموني ب&nbsp;إيثينيليستراديول&nbsp;(على سبيل المثال حبوب منع الحمل عن طريق الفم) أو&nbsp;دانازول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لارتفاع ضغط الدم أو مشاكل في القلب مثل&nbsp;نيفيديبين&nbsp;،&nbsp;نيكارديبين&nbsp;،&nbsp;ديلتيازيم&nbsp;و&nbsp;فيراباميل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لاضطراب النظم القلبي (&nbsp;الأميودارون&nbsp;) تستخدم للسيطرة على عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المعروفة باسم &quot;ستاتينات&quot; المستخدمة لعلاج ارتفاع الكوليسترول والدهون الثلاثية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للصرع&nbsp;الفينيتوين&nbsp;أو&nbsp;الفينوباربيتال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بريدنيزولون&nbsp;(الكورتيكو ستيرويدات )&nbsp;و ميثيل بريدنيزولون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون&nbsp;المضاد للاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المستحضرات&nbsp;العشبية&nbsp;التي تحتوي على&nbsp;نبتة&nbsp;سانت جون&nbsp;(&nbsp;<em>هيبيريكوم</em>&nbsp;<em>بيرفوراتوم</em>&nbsp;) أو خلاصة نبات سكيزاندرا <em>سفينانثيرا</em>&nbsp;<em>.</em></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تحتاج إلى تناول ايبوبروفين،&nbsp;أمفوتريسين&nbsp;بي، أو&nbsp;مضادات الفيروسات&nbsp;(على سبيل المثال&nbsp;أسيكلوفير&nbsp;).&nbsp;هذه قد تفاقم مشاكل الكلى أو الأعراض العصبية عندما تؤخذ جنبا إلى جنب مع&nbsp;كروتال&nbsp;<sup>&reg;</sup>.</p><p dir="RTL">يحتاج طبيبك أيضا لمعرفة ما إذا كنت تتناول مكملات البوتاسيوم أو مدرات البول التي تقتصد البوتاسيوم (على سبيل المثال،&nbsp;أميلوريد&nbsp;،&nbsp;تريامتيرين&nbsp;، أو&nbsp;سبيرونولاكتون&nbsp;)، بعض مسكنات الألم (ما يسمى مضادات الالتهاب غير الستيرويدية، مثل ايبوبروفين)، مضادات التخثر، أو أقراص علاج مرض السكري، أثناء تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>.</p><p dir="RTL">إذا كنت بحاجة إلى أي لقاحات، يرجى إبلاغ الطبيب مسبقا.</p><p dir="RTL"><strong>كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong> <strong>مع الطعام والشراب</strong></p><p dir="RTL">يجب أن تتناول كروتال&nbsp;<sup>&reg;</sup> عموما على معدة فارغة أو على الأقل 1 ساعة قبل أو 2-3 ساعات بعد وجبة الطعام.&nbsp;يجب تجنب عصير الجريب فروت و ثمرة الجريب فروت أثناء تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتي حاملا أو مرضعة، تعتقدين أنك قد تكوني حاملا أو تخططين للإنجاب، اطلبي من طبيبك أو الصيدلي تقديم المشورة قبل تناول هذا الدواء.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup>&nbsp;يفرز في حليب الثدي.&nbsp;لذلك يجب وقف الرضاعة الطبيعية أثناء تناول كروتال&nbsp;<sup>&reg;</sup>&nbsp;.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تدفع أو تستخدم أي أدوات أو آلات إذا كنت تشعر بالدوار أو النعاس، أو لديك مشاكل في الرؤية بوضوح بعد تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>. هذه الأعراض هي أكثر حدوثا إذا&nbsp;تم تناول كروتال&nbsp;&reg; جنبا إلى جنب مع الكحوليات.</p><p dir="RTL"><strong>كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong> <strong>يحتوي على اللاكتوز </strong></p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup> يحتوي على اللاكتوز.&nbsp;إذا قيل لك من قبل طبيبك أن لديك&nbsp;عدم تحمل&nbsp;لبعض السكريات، اتصل بطبيبك قبل تناول هذا المنتج الطبي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup> تماما كما قال لك طبيبك.&nbsp;يجب عليك مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">تأكد من أن تتلقى نفس&nbsp;دواء&nbsp;تاكروليموس في&nbsp;كل مرة تقوم بصرف الوصفة الخاصة بك، إلا إذا وافق أخصائي الزرع الخاص بك إلى التغيير إلى&nbsp;دواء &nbsp;تاكروليموس&nbsp;مختلف&nbsp;.</p><p dir="RTL">يجب تناول هذا الدواء مرتين في اليوم.&nbsp;إذا لم يكن شكل الدواء كالمعتاد، أو إذا تغيرت تعليمات الجرعة، تحدث إلى طبيبك أو الصيدلي في أقرب وقت ممكن للتأكد من حصولك على الدواء المناسب.</p><p dir="RTL">سيتم تحديد جرعة البداية لمنع رفض العضو المزروع من قبل الطبيب وفقا لوزن الجسم.&nbsp;وعادة ما تكون الجرعات الأولية بعد الزرع عموما في نطاق 0.075 - 0.30 ملجم لكل كجم من وزن الجسم يوميا اعتمادا&nbsp;على العضو المزروع.</p><p dir="RTL">تعتمد جرعتك على حالتك العامة وعلى الأدوية الأخرى المثبطة للمناعة التي تتناولها.&nbsp;سيطلب منك طبيبك إجراء فحوص دم منتظمة لتحديد الجرعة الصحيحة وضبط الجرعة من وقت لآخر.&nbsp;طبيبك عادة ما يقلل من&nbsp;جرعة كروتال&nbsp;<sup>&reg;</sup>&nbsp;الخاص بك عندما&nbsp;تستقر&nbsp;حالتك&nbsp;.&nbsp;طبيبك سوف يخبرك بالضبط كم عدد الكبسولات وكم مرة يتم تناولها في اليوم.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup> يؤخذ عن طريق الفم مرتين يوميا، وعادة في الصباح والمساء.&nbsp;يجب أن تتناول كروتال&nbsp;<sup>&reg;</sup>&nbsp;عموما على معدة فارغة أو على الأقل قبل ساعة واحدة أو 2 إلى 3 ساعات بعد الوجبة.&nbsp;يجب ابتلاع الكبسولات كلها مع كوب من الماء.&nbsp;تناول الكبسولات مباشرة بعد إخراجها من الشريط.&nbsp;تجنب عصير الجريب فروت و ثمرة الجريب فروت أثناء تناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;.</p><p dir="RTL"><strong>إذا تناولت كروتال</strong>&nbsp;<strong><sup> &reg;</sup></strong> <strong>أكثر</strong> <strong><sup>&nbsp;</sup></strong><strong>مما يجب</strong></p><p dir="RTL">إذا كنت قد تناولت عن طريق الخطأ الكثير من&nbsp;كروتال&nbsp;<sup>&reg;</sup> راجع طبيبك أو اتصل بأقرب قسم طوارئ في المستشفى على الفور.</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تتناول</strong>&nbsp;<strong>كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعات الفردية المنسية.</p><p dir="RTL">إذا كنت قد نسيت أن تتناول&nbsp;كبسولات كروتال&nbsp;<sup>&reg;</sup>&nbsp;الخاص بك ، انتظر حتى يحين الوقت للجرعة التالية، ومن ثم الاستمرار كما كان من قبل.</p><p dir="RTL"><strong>إذا توقفت عن تناول</strong>&nbsp;<strong>كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong></p><p dir="RTL">وقف العلاج ب&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;قد يزيد من خطر رفض العضو المزروع.&nbsp;لا تتوقف عن علاجك ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية،&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;يمكن أن يسبب أعراض جانبية، وإن لم يكن الجميع يتعرض لها.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup>&nbsp;يقلل من&nbsp;آلية&nbsp;الدفاع&nbsp;الخاصة بك في الجسم&nbsp;لوقف رفض العضو المزروع.&nbsp;وبالتالي، فإن جسمك لن يكون قوي مثل المعتاد في مكافحة العدوى.&nbsp;ولذلك إذا كنت تتناول&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp; يمكنك التقاط المزيد من العدوى أكثر من المعتاد مثل عدوى الجلد والفم والمعدة والأمعاء والرئتين والمسالك البولية.</p><p dir="RTL">قد تحدث أعراض جانبية خطيرة، بما في ذلك الأعراض المذكورة أدناه.&nbsp;أخبر طبيبك فورا إذا كان لديك أو تشك في أنه قد يكون لديك أي من الأعراض الجانبية الخطيرة التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الانتهازية (البكتيريا والفطرية والفيروسية&nbsp;والبروتوزوال&nbsp;): الإسهال لفترات طويلة، والحمى والتهاب الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن&nbsp;الأورام&nbsp;الحميدة والخبيثة&nbsp;بعد العلاج نتيجة&nbsp;لكبت المناعة&nbsp;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرفرية&nbsp;الصفيحات&nbsp;الخثارية&nbsp;: حالة&nbsp;تتميز&nbsp;بالحمى والكدمات تحت الجلد والتي قد تظهر على شكل نقاط حمراء محددة، مع أو بدون تعب شديد غير مبرر، ارتباك، اصفرار الجلد أو العينين (اليرقان)، مع أعراض الفشل الكلوي الحاد (انخفاض أو عدم وجود كمية البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدم تنسج&nbsp;الخلايا الحمراء&nbsp;الواضح (انخفاض حاد جدا في عدد خلايا الدم الحمراء)&nbsp;والانحلالي، &nbsp;تم الإبلاغ عن&nbsp;فقر الدم&nbsp;(انخفاض عدد خلايا الدم الحمراء بسبب انهيار غير طبيعي مصحوبا بالتعب).&nbsp;قد لا يكون لديك أي أعراض اعتمادا على شدة الحالة، قد تشعر: التعب، واللامبالاة، شحوب غير طبيعي في الجلد (شحوب)، وضيق في التنفس، والدوخة، والصداع، وآلام في الصدر والبرودة في اليدين والقدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات&nbsp; ندرة المحببات&nbsp;(انخفاض شديد في عدد خلايا الدم البيضاء المصحوبة بقرحة في الفم والحمى والعدوى).&nbsp;قد لا يكون لديك أي أعراض أو قد تشعر بالحمى المفاجئة، والجهد والتهاب الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية وردود الفعل التحسسية مع الأعراض التالية: طفح ، حكة مفاجئ (ارتكاريا)، تورم في اليدين والقدمين والكاحل والوجه والشفتين والفم أو الحلق (التي قد تسبب صعوبة في البلع أو التنفس) وقد تشعر أنك سوف يغمى عليك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة اعتلال الدماغ الخلفي القابلة للشفاء : صداع، اختلال الحالة العقلية، نوبات، واضطرابات بصرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>تورسادس</em>&nbsp;<em>دي بوينتيس:</em>&nbsp;&nbsp;&nbsp;تغير في تواتر القلب الذي يمكن أن يرافقه أو لا أعراض مثل آلام الصدر (الذبحة الصدرية) أو ضعف أو الدوار أو الغثيان والخفقان (شعور ضربات القلب) وصعوبة في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انثقاب في القناة الهضمية: ألم قوي في البطن مصحوب أو لا مع أعراض أخرى، مثل قشعريرة، حمى، غثيان أو قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز جونسون: ألم الجلد منتشر غير معروف السبب ، تورم في الوجه، تعب شديد مع نفطة الجلد والفم والعين والأعضاء التناسلية، ارتكاريا، تورم اللسان، طفح جلدي أحمر أو أرجواني منتشر، تقطع الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سمية البشرة الانحلالية :&nbsp;تآكل وظهور تقرحات في الجلد أو الأغشية المخاطية، احمرار الجلد وتورمه التي يمكن أن تؤدي إلى انفصال الجلد في أجزاء كبيرة من الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة&nbsp;اليوريك&nbsp;الانحلالية&nbsp; ، حالة مع الأعراض التالية: انخفاض أو عدم وجود البول الناتج (الفشل الكلوي الحاد)، التعب الشديد، اصفرار الجلد أو العينين (&nbsp;الصفراء&nbsp;) و كدمات غير طبيعية أو نزيف وعلامات العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم كفاءة وظيفة العضو المزروع</p><p dir="RTL">الأعراض الجانبية المذكورة أدناه قد تحدث أيضا بعد تلقي&nbsp;كروتال&nbsp;<sup>&reg;</sup>&nbsp;:</p><p dir="RTL"><u>أعراض جانبية شائعة جدا (قد تؤثر على أكثر من 1 من 10 أشخاص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السكر في الدم، وداء السكري، وزيادة البوتاسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رجفة، صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال والغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى</p><p dir="RTL"><u>الأعراض الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض المغنيسيوم والفوسفات والبوتاسيوم والكالسيوم أو الصوديوم في الدم، زيادة السوائل ، وزيادة حمض اليوريك أو الدهون في الدم، وانخفاض الشهية، وزيادة حموضة الدم، والتغيرات الأخرى في أملاح الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض القلق، والارتباك ، والاكتئاب، وتغيرات المزاج، كوابيس، هلوسة، واضطرابات نفسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات، اضطرابات في الوعي، وخز وخدر (مؤلمة في بعض الأحيان) في اليدين والقدمين، والدوخة، وضعف القدرة على الكتابة، واضطرابات الجهاز العصبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، وزيادة الحساسية للضوء، واضطرابات العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين الصوت في أذنيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تدفق الدم في الأوعية الدموية، ضربات القلب السريعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف، انسداد جزئي أو كامل ل الأوعية الدموية، وانخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس، والتغيرات في أنسجة الرئة، وتجمع السوائل حول الرئة، والتهاب البلعوم، والسعال، وأعراض تشبه الانفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات أو قرحة تسبب ألم في البطن أو إسهال، نزف في المعدة، التهابات أو قرحة في الفم، تجمع السوائل في البطن، القيء، آلام في البطن، عسر الهضم، الإمساك، انتفاخ البطن، الانتفاخ، البراز السائل، مشاكل في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغيرات في انزيمات الكبد ووظيفته، اصفرار الجلد بسبب مشاكل الكبد، تلف الأنسجة الكبدية والتهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة، الطفح الجلدي، وفقدان الشعر، حب الشباب، وزيادة التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل، الأطراف أو الظهر، تشنجات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم كفاءة وظيفة الكلى، وانخفاض إنتاج البول، ضعف أو التبول المؤلم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف العام، والحمى، وتجمع السوائل في الجسم، والألم وعدم الراحة، وزيادة انزيم&nbsp;الفوسفاتيز&nbsp;القلوي&nbsp;في الدم، وزيادة الوزن، والشعور بدرجة الحرارة المضطربة</p><p dir="RTL"><u>الأعراض الجانبية غير الشائعة (قد تؤثر على ما يصل إلى 1 من 100 شخص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغييرات في تخثر الدم، وانخفاض جميع عدد خلايا الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف، وانخفاض البروتين أو السكر في الدم، وزيادة الفوسفات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غيبوبة، نزيف في الدماغ، السكتة الدماغية، الشلل، اضطراب الدماغ، تشوهات الكلام واللغة ، مشاكل الذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية بسبب شذوذ في عدسة العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب، توقف ضربات القلب، انخفاض أداء قلبك، اضطراب في عضلة القلب، تضخم عضلة القلب، ضربات القلب أقوى من المعتاد، تخطيط قلب غير طبيعي، ومعدل ضربات القلب ونبض غير طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم في أوردة الأطراف، صدمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس، واضطرابات الجهاز التنفسي، والربو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عرقلة الأمعاء، وزيادة مستوى انزيم الأميليز فى الدم ، ارتداد محتويات المعدة في الحلق، تأخر إفراغ المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد، حرقان في ضوء الشمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التبول، الحيض المؤلم ونزيف الحيض غير الطبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل بعض الأعضاء، الشعور بالمرض مثل الأنفلونزا ، وزيادة الحساسية للحرارة والبرد، والشعور بالضغط على صدرك، والشعور بالعصبية أو شعور غير معتاد، وزيادة انزيم نازعة&nbsp;هيدروجين لاكتات في الدم، وفقدان الوزن</p><p dir="RTL"><u>الأعراض الجانبية النادرة (قد تؤثر على ما يصل إلى 1 في 1000 شخص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف صغير في جلدك بسبب جلطات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة صلابة العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صمم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع السوائل حول القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس الحاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشكيل كيس في البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في تدفق الدم في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العطش، والسقوط، والشعور بضيق في صدرك، وانخفاض الحركة، والقرحة</p><p dir="RTL"><u>أعراض جانبية نادرة جدا (قد تؤثر على ما يصل إلى 1 من 10000 شخص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مخطط صدى القلب غير طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد، وتضيق الأوعية الصفراوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبول مؤلم مع ظهور دم في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الأنسجة الدهنية</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ&nbsp;بعيدا عن متناول و نظر الأطفال.</p><p dir="RTL">تناول الكبسولات&nbsp;مباشرة بعد إخراجها من&nbsp;الشريط.</p><p dir="RTL">لا تستخدم&nbsp;كروتال&nbsp;&reg; بعد تاريخ انتهاء الصلاحية المطبوع على الكرتون بعد كلمة EXP.&nbsp;يشير تاريخ انتهاء الصالحية إلى آخر يوم من ذلك الشهر</p><p dir="RTL">لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يحفظ في العبوة الأصلية من أجل حمايته من الرطوبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong></p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup>&nbsp;&nbsp;&nbsp;0.5 ملجم&nbsp;كبسولات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي&nbsp;تاكروليموس&nbsp;.&nbsp;كل كبسولة تحتوي على 0.5 ملجم من&nbsp;تاكروليموس&nbsp;على هيئة&nbsp;تاكروليموس&nbsp;بريميكس&nbsp;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي&nbsp;:&nbsp;<br />محتوى الكبسولة:&nbsp;كروسكارملوز&nbsp;الصوديوم، مونوهيدرات اللاكتوز،&nbsp;ستيرات&nbsp;المغنيسيوم&nbsp;.&nbsp;<br />غلاف الكبسولة:&nbsp;الحبر الأحمر، الجيلاتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كروتال&nbsp;<sup>&reg;</sup>&nbsp;&nbsp;&nbsp;1 ملجم&nbsp;كبسولات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي&nbsp;تاكروليموس&nbsp;.&nbsp;كل كبسولة تحتوي على 1 ملجم من&nbsp;تاكروليموس&nbsp;على هيئة&nbsp;تاكروليموس&nbsp;بريميكس&nbsp;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي&nbsp;:&nbsp;<br />محتوى الكبسولة:&nbsp;كروسكارملوز&nbsp;الصوديوم، مونوهيدرات اللاكتوز،&nbsp;ستيرات&nbsp;المغنيسيوم&nbsp;.&nbsp;<br />غلاف الكبسولة:&nbsp;الحبر الأحمر، الجيلاتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كروتال&nbsp;<sup>&reg;</sup>&nbsp;&nbsp;&nbsp;5 ملجم&nbsp;كبسولات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي&nbsp;تاكروليموس&nbsp;.&nbsp;كل كبسولة تحتوي على 5 ملجم من&nbsp;تاكروليموس&nbsp;على هيئة تاكروليموس بريميكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي :&nbsp;<br />محتوى الكبسولة:&nbsp;كروسكارملوز&nbsp;الصوديوم، مونوهيدرات اللاكتوز،&nbsp;ستيرات&nbsp;المغنيسيوم&nbsp;.&nbsp;<br />غلاف الكبسولة:&nbsp;الحبر الأبيض، الجيلاتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف</strong>&nbsp;<strong>يبدو كروتال</strong>&nbsp;<strong><sup>&reg;</sup></strong>&nbsp;<strong>ومحتويات العبوة </strong></p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup>&nbsp;0.5 ملجم&nbsp;كبسولات</p><p dir="RTL">كبسولة جيلاتين فارغة صلبة حجم &quot;4&quot; مع غطاء أصفر معتم مطبوع عليه &quot; MG0.5&quot; وجسم أصفر معتم مطبوع عليه &quot;525 RDY&quot; باستخدام الحبر الأحمر.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup>&nbsp;1 ملجم&nbsp;كبسولات</p><p dir="RTL">كبسولة جيلاتين فارغة صلبة حجم &quot;4&quot; مع غطاء أبيض معتم مطبوع عليه &quot;1MG&quot; وجسم أبيض معتم مطبوع عليه &quot;526 RDY&quot; باستخدام الحبر الأحمر.</p><p dir="RTL">كروتال&nbsp;<sup>&reg;</sup>&nbsp;5 ملجم&nbsp;كبسولات</p><p dir="RTL">كبسولة جيلاتين فارغة صلبة حجم &quot;4&quot; مع غطاء أحمر رمادي معتم مطبوع عليه &quot;5 mg&quot; وجسم أحمر رمادي غامق معتم مطبوع عليه &quot;527 RDY&quot; باستخدام الحبر الأبيض.</p><p dir="RTL">كل تركيز يسوق على هيئة: &nbsp;100 كبسولة / 10 شرائط/ وحدة الكرتون.</p><p dir="RTL">كل شريط يحتوي علي 10 كبسولات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صنع بواسطة</strong></p><p dir="RTL">مختبرات الدكتور ريدي المحدودة</p><p dir="RTL"><strong>لصالح</strong></p><p dir="RTL">الدوائية</p><p dir="RTL">مصنع الأدوية بالقصيم،</p><p dir="RTL">المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2019.                                         
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CROTAL® 0.5 mg capsules
CROTAL 1 mg capsules
CROTAL 5 mg capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CROTAL® 0.5 mg capsules
Each capsule contains 0.5 mg of Tacrolimus PreMix
Excipient with known effect: 134 mg of lactose monohydrate

CROTAL 1 mg capsules
Each capsule contains 1 mg of Tacrolimus PreMix
Excipient with known effect: 131.5 mg of lactose monohydrate

CROTAL 5 mg capsules
Each capsule contains 5 mg of tacrolimus (as monohydrate).
Excipient with known effect: 111.5 mg of lactose monohydrate
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CROTAL® 0.5 mg capsules
Size “4” empty hard gelatin capsule shell with dark yellow opaque cap imprinted with “0.5 MG” and dark yellow opaque body imprinted with “RDY 525” using red ink.
CROTAL 1 mg capsules
Size "4" empty hard gelatin capsule shell with white opaque cap imprinted with "1MG" and white opaque body imprinted with "RDY 526" using red ink
CROTAL 5 mg capsules
Size "4" empty hard gelatin capsule shell with dark greyish red opaque cap imprinted with "5MG" and dark greyish red opaque body imprinted with "RDY 527" using white ink.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients.</p><p>Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CROTAL therapy requires careful monitoring by adequately qualified and equipped personnel. The medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients.</p><p>Inadvertent, unintentional or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe. This can lead to graft rejection or increased incidence of side effects, including under- or over-immunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.</p><p><strong>General considerations</strong></p><p>The recommended initial dosages presented below are intended to act solely as a guideline. CROTAL dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring (see below for recommended target whole blood trough concentrations). If clinical signs of rejection are apparent, alteration of the immunosuppressive regimen should be considered.</p><p>CROTAL can be administered intravenously or orally. In general, dosing may commence orally; if necessary, by administering the capsule contents suspended in water, via nasogastric tubing.</p><p>CROTAL is routinely administered in conjunction with other immunosuppressive agents in the initial post-operative period. The CROTAL dose may vary depending upon the immunosuppressive regimen chosen.</p><p><strong>Method of administration</strong></p><p>It is recommended that the oral daily dose be administered in two divided doses (e.g. morning and evening). Capsules should be taken immediately following removal from the blister. Patients should be advised not to swallow the desiccant. The capsules should be swallowed with fluid (preferably water).</p><p>Capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption (see section 5.2).</p><p><strong>Duration of dosing</strong></p><p>To suppress graft rejection, immunosuppression must be maintained; consequently, no limit to the duration of oral therapy can be given.</p><p><strong>Dosage recommendations &ndash; Liver transplantation</strong></p><p><u>Prophylaxis of transplant rejection - adults</u></p><p>Oral CROTAL therapy should commence at 0.10 - 0.20 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence approximately 12 hours after the completion of surgery.</p><p>If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.01 - 0.05 mg/kg/day should be initiated as a continuous 24-hour infusion.</p><p><u>Prophylaxis of transplant rejection - children</u></p><p>An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening). If the clinical condition of the patient prevents oral dosing, an initial intravenous dose of 0.05 mg/kg/day should be administered as a continuous 24-hour infusion.</p><p><u>Dose adjustment during post-transplant period in adults and children</u></p><p>CROTAL doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to CROTAL monotherapy. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Rejection therapy &ndash; adults and children</u></p><p>Increased CROTAL doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are noted (e.g. pronounced adverse reactions - see section 4.8) the dose of CROTAL may need to be reduced.</p><p>For conversion to CROTAL, treatment should begin with the initial oral dose recommended for primary immunosuppression.</p><p>For information on conversion from ciclosporin to CROTAL, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p><strong>Dosage recommendations - Kidney transplantation</strong></p><p><u>Prophylaxis of transplant rejection &ndash; adults</u></p><p>Oral CROTAL therapy should commence at 0.20 - 0.30 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 24 hours after the completion of surgery.</p><p>If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.05 - 0.10 mg/kg/day should be initiated as a continuous 24-hour infusion.</p><p><u>Prophylaxis of transplant rejection &ndash; children</u></p><p>An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening). If the clinical condition of the patient prevents oral dosing, an initial intravenous dose of 0.075 &ndash; 0.100 mg/kg/day should be administered as a continuous 24-hour infusion.</p><p><u>Dose adjustment during post-transplant period in adults and children</u></p><p>CROTAL doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to CROTAL-based dual-therapy. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Rejection therapy &ndash; adults and children</u></p><p>Increased CROTAL doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are noted (e.g. pronounced adverse reactions - see section 4.8) the dose of CROTAL may need to be reduced.</p><p>For conversion to CROTAL, treatment should begin with the initial oral dose recommended for primary immunosuppression.</p><p>For information on conversion from ciclosporin to CROTAL, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p><strong>Dosage recommendations - Heart transplantation</strong></p><p><u>Prophylaxis of transplant rejection &ndash; adults</u></p><p>CROTAL can be used with antibody induction (allowing for delayed start of CROTAL therapy) or alternatively in clinically stable patients without antibody induction.</p><p>Following antibody induction, oral CROTAL therapy should commence at a dose of 0.075 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 5 days after the completion of surgery as soon as the patient&#39;s clinical condition is stabilised. If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.01 to 0.02 mg/kg/day should be initiated as a continuous 24-hour infusion.</p><p>An alternative strategy was published where oral tacrolimus was administered within 12 hours post transplantation. This approach was reserved for patients without organ dysfunction (e.g. renal dysfunction). In that case, an initial oral tacrolimus dose of 2 to 4 mg per day was used in combination with mycophenolate mofetil and corticosteroids or in combination with sirolimus and corticosteroids.</p><p><u>Prophylaxis of transplant rejection &ndash; children</u></p><p>CROTAL has been used with or without antibody induction in paediatric heart transplantation.</p><p>In patients without antibody induction, if CROTAL therapy is initiated intravenously, the recommended starting dose is 0.03 - 0.05 mg/kg/day as a continuous 24-hour infusion targeted to achieve tacrolimus whole blood concentrations of 15 - 25 ng/ml. Patients should be converted to oral therapy as soon as clinically practicable. The first dose of oral therapy should be 0.30 mg/kg/day starting 8 to 12 hours after discontinuing intravenous therapy.</p><p>Following antibody induction, if CROTAL therapy is initiated orally, the recommended starting dose is 0.10 - 0.30 mg/kg/day administered as two divided doses (e.g. morning and evening).</p><p><u>Dose adjustment during post-transplant period in adults and children</u></p><p>CROTAL doses are usually reduced in the post-transplant period. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Rejection therapy &ndash; adults and children</u></p><p>Increased CROTAL doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes.</p><p>In adult patients converted to CROTAL, an initial oral dose of 0.15 mg/kg/day should be administered in two divided doses (e.g. morning and evening).</p><p>In paediatric patients converted to CROTAL, an initial oral dose of 0.20 - 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening).</p><p>For information on conversion from ciclosporin to CROTAL, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p><strong>Dosage recommendations - Rejection therapy, other allografts</strong></p><p>The dose recommendations for lung, pancreas and intestinal transplantation are based on limited prospective clinical trial data. In lung-transplanted patients CROTAL has been used at an initial oral dose of 0.10 - 0.15 mg/kg/day, in pancreas-transplanted patients at an initial oral dose of 0.2 mg/kg/day and in intestinal transplantation at an initial oral dose of 0.3 mg/kg/day.</p><p><strong>Dosage adjustments in specific patient populations</strong></p><p><u>Patients with liver impairment</u></p><p>Dose reduction may be necessary in patients with severe liver impairment in order to maintain the blood trough levels within the recommended target range.</p><p><u>Patients with kidney impairment</u></p><p>As the pharmacokinetics of tacrolimus are unaffected by renal function, no dose adjustment should be required. However, owing to the nephrotoxic potential of tacrolimus careful monitoring of renal function is recommended (including serial serum creatinine concentrations, calculation of creatinine clearance and monitoring of urine output).</p><p><u>Paediatric patients</u></p><p>In general, paediatric patients require doses 1&frac12; - 2 times higher than the adult doses to achieve similar blood levels.</p><p><u>Older people</u></p><p>There is no evidence currently available to indicate that dosing should be adjusted in older people.</p><p><u>Conversion from ciclosporin</u></p><p>Care should be taken when converting patients from ciclosporin-based to CROTAL-based therapy (see sections 4.4 and 4.5). CROTAL therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient. Dosing should be delayed in the presence of elevated ciclosporin blood levels. In practice, CROTAL therapy has been initiated 12 - 24 hours after discontinuation of ciclosporin. Monitoring of ciclosporin blood levels should be continued following conversion as the clearance of ciclosporin might be affected.</p><p><strong>Target whole blood trough concentration recommendations</strong></p><p>Dosing should primarily be based on clinical assessments of rejection and tolerability in each individual patient.</p><p>As an aid to optimise dosing, several immunoassays are available for determining tacrolimus concentrations in whole blood including a semi-automated microparticle enzyme immunoassay (MEIA). Comparisons of concentrations from the published literature to individual values in clinical practice should be assessed with care and knowledge of the assay methods employed. In current clinical practice, whole blood levels are monitored using immunoassay methods.</p><p>Blood trough levels of tacrolimus should be monitored during the post-transplantation period. When dosed orally, blood trough levels should be drawn approximately 12 hours post-dosing, just prior to the next dose. The frequency of blood level monitoring should be based on clinical needs. As CROTAL is a medicinal product with low clearance, adjustments to the dosage regimen may take several days before changes in blood levels are apparent. Blood trough levels should be monitored approximately twice weekly during the early post-transplant period and then periodically during maintenance therapy. Blood trough levels of tacrolimus should also be monitored following dose adjustment, changes in the immunosuppressive regimen, or following co-administration of substances which may alter tacrolimus whole blood concentrations (see section 4.5).</p><p>Clinical study analysis suggests that the majority of patients can be successfully managed if tacrolimus blood trough levels are maintained below 20 ng/ml. It is necessary to consider the clinical condition of the patient when interpreting whole blood levels.</p><p>In clinical practice, whole blood trough levels have generally been in the range 5 - 20 ng/ml in liver transplant recipients and 10 - 20 ng/ml in kidney and heart transplant patients in the early post-transplant period. Subsequently, during maintenance therapy, blood concentrations have generally been in the range of 5 - 15 ng/ml in liver, kidney and heart transplant recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to tacrolimus or other macrolides.
Hypersensitivity to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. This has led to serious adverse events, including graft rejection, or other side effects which could be a consequence of either under- or over-exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8).</p><p>During the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations. If clinically relevant changes are seen, adjustments of the immunosuppressive regimen should be considered.</p><p><u>Substances with potential for interaction</u></p><p>When substances with a potential for interaction (see section 4.5) - particularly strong inhibitors of CYP3A4 (such as telaprevir, boceprevir, ritonavir, ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampicin, rifabutin) &ndash; are being combined with tacrolimus, tacrolimus blood levels should be monitored to adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure.</p><p>Herbal preparations containing St. John&#39;s wort (Hypericum perforatum) or other herbal preparations should be avoided when taking CROTAL due to the risk of interactions that lead to either a decrease in blood concentrations of tacrolimus and reduced clinical effect of tacrolimus, or an increase in blood concentrations of tacrolimus and risk of tacrolimus toxicity (see section 4.5).</p><p>The combined administration of ciclosporin and tacrolimus should be avoided and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.5).</p><p>High potassium intake or potassium-sparing diuretics should be avoided (see section 4.5).</p><p>Certain combinations of tacrolimus with drugs known to have nephrotoxic or neurotoxic effects may increase the risk of these effects (see section 4.5).</p><p><u>Vaccination</u></p><p>Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided.</p><p><u>Gastrointestinal disorders</u></p><p>Gastrointestinal perforation has been reported in patients treated with tacrolimus. As gastrointestinal perforation is a medically important event that may lead to a life-threatening or serious condition, adequate treatments should be considered immediately after suspected symptoms or signs occur.</p><p>Since levels of tacrolimus in blood may significantly change during diarrhoea episodes, extra monitoring of tacrolimus concentrations is recommended during episodes of diarrhoea.</p><p><u>Cardiac disorders</u></p><p>Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies, have been observed on rare occasions. Most cases have been reversible, occurring primarily in children with tacrolimus blood trough concentrations much higher than the recommended maximum levels. Other factors observed to increase the risk of these clinical conditions included pre-existing heart disease, corticosteroid usage, hypertension, renal or hepatic dysfunction, infections, fluid overload, and oedema. Accordingly, high-risk patients, particularly young children and those receiving substantial immunosuppression should be monitored, using such procedures as echocardiography or ECG pre- and post-transplant (e.g. initially at three months and then at 9-12 months). If abnormalities develop, dose reduction of CROTAL therapy, or change of treatment to another immunosuppressive agent should be considered. Tacrolimus may prolong the QT interval and may cause&nbsp;<em>Torsades de Pointes</em>. Caution should be exercised in patients with risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities. Caution should also be exercised in patients diagnosed or suspected to have Congenital Long QT Syndrome or acquired QT prolongation or patients on concomitant medications known to prolong the QT interval, induce electrolyte abnormalities or known to increase tacrolimus exposure (see section 4.5).</p><p><u>Lymphoproliferative disorders and malignancies</u></p><p>Patients treated with CROTAL have been reported to develop Epstein-Barr Virus (EBV)-associated lymphoproliferative disorders (see section 4.8). Patients switched to CROTAL therapy should not receive anti-lymphocyte treatment concomitantly. Very young (&lt; 2 years), EBV-VCA-negative children have been reported to have an increased risk of developing lymphoproliferative disorders. Therefore, in this patient group, EBV-VCA serology should be ascertained before starting treatment with CROTAL. During treatment, careful monitoring with EBV-PCR is recommended. Positive EBV-PCR may persist for months and is per se not indicative of lymphoproliferative disease or lymphoma.</p><p>As with other immunosuppressive agents, owing to the potential risk of malignant skin changes, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p>As with other potent immunosuppressive compounds, the risk of secondary cancer is unknown (see section 4.8).</p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u></p><p>Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). If patients taking tacrolimus present with symptoms indicating PRES such as headache, altered mental status, seizures, and visual disturbances, a radiological procedure (e.g. MRI) should be performed. If PRES is diagnosed, adequate blood pressure control and immediate discontinuation of systemic tacrolimus is advised. Most patients completely recover after appropriate measures are taken.</p><p><u>Opportunistic infections</u></p><p>Patients treated with immunosuppressants, including CROTAL are at increased risk of opportunistic infections (bacterial, fungal, viral and protozoal). Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML). These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in patients with deteriorating renal function or neurological symptoms.</p><p><u>Pure Red Cell Aplasia</u></p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus.</p><p>All patients reported risk factors for PRCA such as parvovirus B19 infection, underlying disease or concomitant medications associated with PRCA.</p><p><u>Excipients</u></p><p>As CROTAL contains lactose, special care should be taken in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.</p><p>The printing ink used to mark CROTAL capsules 0.5 mg and 1mg contains soya lecithin. In patients who are hypersensitive to peanut or soya, the risk and severity of hypersensitivity should be weighed against the benefit of using CROTAL.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Metabolic interactions</u></p><p>Systemically available tacrolimus is metabolised by hepatic CYP3A4. There is also evidence of gastrointestinal metabolism by CYP3A4 in the intestinal wall. Concomitant use of medicinal products or herbal remedies known to inhibit or induce CYP3A4 may affect the metabolism of tacrolimus and thereby increase or decrease tacrolimus blood levels. It is therefore strongly recommended to closely monitor tacrolimus blood levels, as well as QT prolongation (with ECG), renal function and other side effects, whenever substances which have the potential to alter CYP3A4 metabolism are used concomitantly and to interrupt or adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure (see sections 4.2 and 4.4).</p><p><u>Inhibitors of metabolism</u></p><p>Clinically the following substances have been shown to increase tacrolimus blood levels:</p><p>Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole and voriconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir) or HCV protease inhibitors (e.g. telaprevir, boceprevir). Concomitant use of these substances may require decreased tacrolimus doses in nearly all patients.</p><p>Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, amiodarone, danazol, ethinylestradiol, omeprazole, nefazodone and (Chinese) herbal remedies containing extracts of&nbsp;<em>Schisandra sphenanthera</em>.</p><p><em>In vitro</em>&nbsp;the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen, troleandomycin.</p><p>Grapefruit juice has been reported to increase the blood level of tacrolimus and should therefore be avoided.</p><p>Lansoprazole and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and thereby increase tacrolimus whole blood concentrations.</p><p><u>Other interactions potentially leading to increased tacrolimus blood levels</u></p><p>Tacrolimus is extensively bound to plasma proteins. Possible interactions with other medicinal products known to have high affinity for plasma proteins should be considered (e.g., NSAIDs, oral anticoagulants, or oral antidiabetics).</p><p>Other potential interactions that may increase systemic exposure of tacrolimus include the prokinetic agent metoclopramide, cimetidine and magnesium-aluminium-hydroxide.</p><p><u>Inducers of metabolism</u></p><p>Clinically the following substances have been shown to decrease tacrolimus blood levels:</p><p>Strong interactions have been observed with rifampicin, phenytoin or St. John&#39;s Wort (<em>Hypericum perforatum</em>) which may require increased tacrolimus doses in almost all patients. Clinically significant interactions have also been observed with phenobarbital. Maintenance doses of corticosteroids have been shown to reduce tacrolimus blood levels.</p><p>High dose prednisolone or methylprednisolone administered for the treatment of acute rejection have the potential to increase or decrease tacrolimus blood levels.</p><p>Carbamazepine, metamizole and isoniazid have the potential to decrease tacrolimus concentrations.</p><p><u>Effect of tacrolimus on the metabolism of other medicinal products</u></p><p>Tacrolimus is a known CYP3A4 inhibitor; thus concomitant use of tacrolimus with medicinal products known to be metabolised by CYP3A4 may affect the metabolism of such medicinal products.</p><p>The half-life of ciclosporin is prolonged when tacrolimus is given concomitantly. In addition, synergistic/additive nephrotoxic effects can occur. For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4).</p><p>Tacrolimus has been shown to increase the blood level of phenytoin.</p><p>As tacrolimus may reduce the clearance of steroid-based contraceptives leading to increased hormone exposure, particular care should be exercised when deciding upon contraceptive measures.</p><p>Limited knowledge of interactions between tacrolimus and statins is available. Available data suggests that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus.</p><p>Animal data have shown that tacrolimus could potentially decrease the clearance and increase the half-life of pentobarbital and phenazone.</p><p><u>Other interactions which have led to clinically detrimental effects</u></p><p>Concurrent use of tacrolimus with medicinal products known to have nephrotoxic or neurotoxic effects may increase these effects (e.g., aminoglycosides, gyrase inhibitors, vancomycin, sulfamethoxazole+trimethoprim, NSAIDs, ganciclovir or aciclovir).</p><p>Enhanced nephrotoxicity has been observed following the administration of amphotericin B and ibuprofen in conjunction with tacrolimus.</p><p>As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g., amiloride, triamterene, or spironolactone) should be avoided (see section 4.4).</p><p>Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Human data show that tacrolimus is able to cross the placenta. Limited data from organ transplant recipients show no evidence of an increased risk of adverse effects on the course and outcome of pregnancy under tacrolimus treatment compared with other immunosuppressive medicinal products. However, cases of spontaneous abortion have been reported. To date, no other relevant epidemiological data are available. Due to the need of treatment, tacrolimus can be considered in pregnant women when there is no safer alternative and when the perceived benefit justifies the potential risk to the foetus. In case of&nbsp;<em>in utero</em>&nbsp;exposure, monitoring of the newborn for the potential adverse effects of tacrolimus is recommended (in particular the effects on the kidneys). There is a risk for premature delivery (&lt;37 week) as well as for hyperkalaemia in the newborn, which, however, normalizes spontaneously.</p><p>In rats and rabbits, tacrolimus caused embryofoetal toxicity at doses which demonstrated maternal toxicity (see section 5.3).</p><p><u>Breast-feeding</u></p><p>Human data demonstrate that tacrolimus is excreted into breast milk. As detrimental effects on the newborn cannot be excluded, women should not breast-feed whilst receiving CROTAL.</p><p><u>Fertility</u></p><p>A negative effect of tacrolimus on male fertility in the form of reduced sperm counts and motility was observed in rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus may cause visual and neurological disturbances. This effect may be enhanced if CROTAL is administered in association with alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse drug reaction profile associated with immunosuppressive agents is often difficult to establish owing to the underlying disease and the concurrent use of multiple medications.</p><p>Many of the adverse drug reactions stated below are reversible and/or respond to dose reduction. Oral administration appears to be associated with a lower incidence of adverse drug reactions compared with intravenous use. Adverse drug reactions are listed below in descending order by frequency of occurrence: very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1,000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p><u>Infections and infestations</u></p><p>As is well known for other potent immunosuppressive agents, patients receiving tacrolimus are frequently at increased risk for infections (viral, bacterial, fungal, protozoal). The course of pre-existing infections may be aggravated. Both generalised and localised infections can occur.</p><p>Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including CROTAL.</p><p><u>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</u></p><p>Patients receiving immunosuppressive therapy are at increased risk of developing malignancies. Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>anaemia, leukopenia, thrombocytopenia, leukocytosis, red blood cell analyses abnormal</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>coagulopathies, coagulation and bleeding analyses abnormal, pancytopenia, neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>thrombotic thrombocytopenic purpura, hypoprothrombinaemia</p></td></tr><tr><td style="vertical-align:top"><p>not known:</p></td><td style="vertical-align:top"><p>pure red cell aplasia, agranulocytosis, haemolytic anaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Immune system disorders</u></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Allergic and anaphylactoid reactions have been observed in patients receiving tacrolimus (see section 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Endocrine disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>hirsutism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Metabolism and nutrition disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>very common:</p></td><td style="vertical-align:top"><p>hyperglycaemic conditions, diabetes mellitus, hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>hypomagnesaemia, hypophosphataemia, hypokalaemia, hypocalcaemia, hyponatraemia, fluid overload, hyperuricaemia, appetite decreased, metabolic acidoses, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, other electrolyte abnormalities</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>dehydration, hypoproteinaemia, hyperphosphataemia, hypoglycaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Psychiatric disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>very common:</p></td><td style="vertical-align:top"><p>insomnia</p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>anxiety symptoms, confusion and disorientation, depression, depressed mood, mood disorders and disturbances, nightmare, hallucination, mental disorders</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>psychotic disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Nervous system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>very common:</p></td><td style="vertical-align:top"><p>tremor, headache</p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>seizures, disturbances in consciousness, paraesthesias and dysaesthesias, peripheral neuropathies, dizziness, writing impaired, nervous system disorders</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>coma, central nervous system haemorrhages and cerebrovascular accidents, paralysis and paresis, encephalopathy, speech and language abnormalities, amnesia</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>hypertonia</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>myasthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Eye disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>vision blurred, photophobia, eye disorders</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>cataract</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>blindness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Ear and labyrinth disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>hypoacusis</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>deafness neurosensory</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>hearing impaired</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Cardiac disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>ischaemic coronary artery disorders, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>ventricular arrhythmias and cardiac arrest, heart failures, cardiomyopathies, ventricular hypertrophy, supraventricular arrhythmias, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>pericardial effusion</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p><em>Torsades de Pointes</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>very common:</p></td><td style="vertical-align:top"><p>hypertension</p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>haemorrhage, thrombembolic and ischaemic events, peripheral vascular disorders, vascular hypotensive disorders</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>infarction, venous thrombosis deep limb, shock</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Respiratory, thoracic and mediastinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>dyspnoea, parenchymal lung disorders, pleural effusion, pharyngitis, cough, nasal congestion and inflammations</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>respiratory failures, respiratory tract disorders, asthma</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>acute respiratory distress syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>very common:</p></td><td style="vertical-align:top"><p>diarrhoea, nausea</p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>gastrointestinal inflammatory conditions, gastrointestinal ulceration and perforation, gastrointestinal haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and symptoms</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>ileus paralytic, acute and chronic pancreatitis, gastrooesophageal reflux disease, impaired gastric emptying</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>subileus, pancreatic pseudocyst</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>hepatitic artery thrombosis, venoocclusive liver disease</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>hepatic failure, bile duct stenosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>pruritus, rash, alopecias, acne, sweating increased</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>dermatitis, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis (Lyell&#39;s syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>Stevens Johnson syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Musculoskeletal and connective tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>arthralgia, muscle spasms, pain in limb, back pain</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>joint disorders</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>mobility decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>very common:</p></td><td style="vertical-align:top"><p>renal impairment</p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>renal failure, renal failure acute, oliguria, renal tubular necrosis, nephropathy toxic, urinary abnormalities, bladder and urethral symptoms</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>anuria, haemolytic uraemic syndrome</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>nephropathy, cystitis haemorrhagic</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Reproductive system and breast disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>dysmenorrhoea and uterine bleeding</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>asthenic conditions, febrile disorders, oedema, pain and discomfort, body temperature perception disturbed</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>multi-organ failure, influenza like illness, temperature intolerance, chest pressure sensation, feeling jittery, feeling abnormal</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>thirst, fall, chest tightness, ulcer</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>fat tissue increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Investigations</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>hepatic enzymes and function abnormalities, blood alkaline phosphatase increased, weight increased</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>amylase increased, ECG investigations abnormal, heart rate and pulse investigations abnormal, weight decreased, blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>echocardiogram abnormal, electrocardiogram QT prolonged</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Injury, poisoning and procedural complications</u></p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>primary graft dysfunction</p></td></tr></tbody></table><p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. A number of associated cases of transplant rejection have been reported (frequency cannot be estimated from available data).</p><p><u>Description of selected adverse reactions</u></p><p>Pain in extremity has been described in a number of published case reports as part of Calcineurin-Inhibitor Induced Pain Syndrome (CIPS). This typically presents as a bilateral and symmetrical, severe, ascending pain in the lower extremities and may be associated with supra-therapeutic levels of tacrolimus. The syndrome may respond to tacrolimus dose reduction. In some cases, it was necessary to switch to alternative immunosuppression.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-2038222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exts: 2317-2356-2340.</p><p>Hot line: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with overdosage is limited. Several cases of accidental overdosage have been reported; symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy, increased blood urea nitrogen and elevated serum creatinine concentrations, and increase in alanine aminotransferase levels.</p><p>No specific antidote to CROTAL therapy is available. If overdosage occurs, general supportive measures and symptomatic treatment should be conducted.</p><p>Based on its high molecular weight, poor aqueous solubility, and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus will not be dialysable. In isolated patients with very high plasma levels, haemofiltration or -diafiltration have been effective in reducing toxic concentrations. In cases of oral intoxication, gastric lavage and/or the use of adsorbents (such as activated charcoal) may be helpful, if used shortly after intake.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Calcineurin inhibitors, ATC code: L04AD02</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p>At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound. The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of lymphokine genes.</p><p>Tacrolimus is a highly potent immunosuppressive agent and has proven activity in both&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;experiments.</p><p>In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and &gamma;-interferon) and the expression of the interleukin-2 receptor.</p><p><u>Results from published data in other primary organ transplantation</u></p><p>CROTAL has evolved into an accepted treatment as primary immunosuppressive medicinal product following pancreas, lung and intestinal transplantation. In prospective published studies tacrolimus was investigated as primary immunosuppressant in approximately 175 patients following lung, 475 patients following pancreas and 630 patients following intestinal transplantation. Overall, the safety profile of tacrolimus in these published studies appeared to be similar to what was reported in the large studies, where tacrolimus was used as primary treatment in liver, kidney and heart transplantation. Efficacy results of the largest studies in each indication are summarised below.</p><p><u>Lung transplantation</u></p><p>The interim analysis of a recent multicentre study discussed 110 patients who underwent 1:1 randomisation to either tacrolimus or ciclosporin. Tacrolimus was started as continuous intravenous infusion at a dose of 0.01 to 0.03 mg/kg/day and oral tacrolimus was administered at a dose of 0.05 to 0.3 mg/kg/day. A lower incidence of acute rejection episodes for tacrolimus- versus ciclosporin-treated patients (11.5% versus 22.6%) and a lower incidence of chronic rejection, the bronchiolitis obliterans syndrome (2.86% versus 8.57%), was reported within the first year after transplantation. The 1-year patient survival rate was 80.8% in the tacrolimus and 83% in the ciclosporin group (Treede et al., 3<sup>rd</sup>&nbsp;ICI San Diego, US, 2004;Abstract 22).</p><p>Another randomised study included 66 patients on tacrolimus versus 67 patients on ciclosporin. Tacrolimus was started as continuous intravenous infusion at a dose of 0.025 mg/kg/day and oral tacrolimus was administered at a dose of 0.15 mg/kg/day with subsequent dose adjustments to target trough levels of 10 to 20 ng/ml. The 1-year patient survival was 83% in the tacrolimus and 71% in the ciclosporin group, the 2-year survival rates were 76% and 66%, respectively. Acute rejection episodes per 100 patient-days were numerically fewer in the tacrolimus (0.85 episodes) than in the ciclosporin group (1.09 episodes). Obliterative bronchiolitis developed in 21.7% of patients in the tacrolimus group compared with 38.0% of patients in the ciclosporin group (p = 0.025). Significantly more ciclosporin-treated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995;60:580).</p><p>In an additional two-centre study, 26 patients were randomised to the tacrolimus versus 24 patients to the ciclosporin group. Tacrolimus was started as continuous intravenous infusion at a dose of 0.05 mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3 mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 ng/ml. The 1-year survival rates were 73.1% in the tacrolimus versus 79.2% in the ciclosporin group. Freedom from acute rejection was higher in the tacrolimus group at 6 months (57.7% versus 45.8%) and at 1 year after lung transplantation (50% versus 33.3%) (Treede et al., J Heart Lung Transplant 2001;20:511).</p><p>The three studies demonstrated similar survival rates. The incidences of acute rejection were numerically lower with tacrolimus in all three studies and one of the studies reported a significantly lower incidence of bronchiolitis obliterans syndrome with tacrolimus.</p><p><u>Pancreas transplantation</u></p><p>A multicentre study included 205 patients undergoing simultaneous pancreas-kidney transplantation who were randomised to tacrolimus (n=103) or to ciclosporin (n=102). The initial oral per protocol dose of tacrolimus was 0.2 mg/kg/day with subsequent dose adjustments to target trough levels of 8 to 15 ng/ml by Day 5 and 5 to 10 ng/mL after Month 6. Pancreas survival at 1 year was significantly superior with tacrolimus: 91.3% versus 74.5% with ciclosporin (p &lt; 0.0005), whereas renal graft survival was similar in both groups. In total 34 patients switched treatment from ciclosporin to tacrolimus, whereas only 6 tacrolimus patients required alternative therapy (Bechstein et al., Transplantation 2004;77:1221).</p><p><u>Intestinal transplantation</u></p><p>Published clinical experience from a single centre on the use of tacrolimus for primary treatment following intestinal transplantation showed that the actuarial survival rate of 155 patients (65 intestine alone, 75 liver and intestine, and 25 multivisceral) receiving tacrolimus and prednisone was 75% at 1 year, 54% at 5 years, and 42% at 10 years. In the early years the initial oral dose of tacrolimus was 0.3 mg/kg/day. Results continuously improved with increasing experience over the course of 11 years. A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time (Abu-Elmagd et al., Ann Surg 2001;234:404).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>In man tacrolimus has been shown to be able to be absorbed throughout the gastrointestinal tract. Following oral administration of CROTAL capsules peak concentrations (C<sub>max</sub>) of tacrolimus in blood are achieved in approximately 1 - 3 hours. In some patients, tacrolimus appears to be continuously absorbed over a prolonged period yielding a relatively flat absorption profile. The mean oral bioavailability of tacrolimus is in the range of 20% - 25%.</p><p>After oral administration (0.30 mg/kg/day) to liver transplant patients, steady-state concentrations of CROTAL were achieved within 3 days in the majority of patients.</p><p>In healthy subjects, CROTAL 0.5 mg, CROTAL 1 mg and CROTAL 5 mg Capsules, hard have been shown to be bioequivalent, when administered as equivalent dose.</p><p>The rate and extent of absorption of tacrolimus is greatest under fasted conditions. The presence of food decreases both the rate and extent of absorption of tacrolimus, the effect being most pronounced after a high-fat meal. The effect of a high-carbohydrate meal is less pronounced.</p><p>In stable liver transplant patients, the oral bioavailability of CROTAL was reduced when it was administered after a meal of moderate fat (34% of calories) content. Decreases in AUC (27%) and C<sub>max&nbsp;</sub>(50%), and an increase in t<sub>max</sub>&nbsp;(173%) in whole blood were evident.</p><p>In a study of stable renal transplant patients who were administered CROTAL immediately after a standard continental breakfast the effect on oral bioavailability was less pronounced. Decreases in AUC (2 to 12%) and C<sub>max</sub>&nbsp;(15 to 38%), and an increase in t<sub>max</sub>&nbsp;(38 to 80%) in whole blood were evident.</p><p>Bile flow does not influence the absorption of CROTAL.</p><p>A strong correlation exists between AUC and whole blood trough levels at steady-state. Monitoring of whole blood trough levels therefore provides a good estimate of systemic exposure.</p><p><u>Distribution and elimination</u></p><p>In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic.</p><p>In the systemic circulation, tacrolimus binds strongly to erythrocytes resulting in an approximate 20:1 distribution ratio of whole blood/plasma concentrations. In plasma, tacrolimus is highly bound (&gt; 98.8%) to plasma proteins, mainly to serum albumin and &alpha;-1-acid glycoprotein.</p><p>Tacrolimus is extensively distributed in the body. The steady-state volume of distribution based on plasma concentrations is approximately 1300 l (healthy subjects). Corresponding data based on whole blood averaged 47.6 l.</p><p>Tacrolimus is a low-clearance substance. In healthy subjects, the average total body clearance (TBC) estimated from whole blood concentrations was 2.25 l/h. In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed. Paediatric liver transplant recipients have a TBC approximately twice that of adult liver transplant patients. Factors such as low haematocrit and protein levels, which result in an increase in the unbound fraction of tacrolimus, or corticosteroid-induced increased metabolism are considered to be responsible for the higher clearance rates observed following transplantation.</p><p>The half-life of tacrolimus is long and variable. In healthy subjects, the mean half-life in whole blood is approximately 43 hours. In adult and paediatric liver transplant patients, it averaged 11.7 hours and 12.4 hours, respectively, compared with 15.6 hours in adult kidney transplant recipients. Increased clearance rates contribute to the shorter half-life observed in transplant recipients.</p><p><u>Metabolism and biotransformation</u></p><p>Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4. Tacrolimus is also considerably metabolised in the intestinal wall. There are several metabolites identified. Only one of these has been shown<em>&nbsp;in vitro&nbsp;</em>to have immunosuppressive activity similar to that of tacrolimus. The other metabolites have only weak or no immunosuppressive activity. In systemic circulation only one of the inactive metabolites is present at low concentrations. Therefore, metabolites do not contribute to pharmacological activity of tacrolimus.</p><p><u>Excretion</u></p><p>Following intravenous and oral administration of&nbsp;<sup>14</sup>C-labelled tacrolimus, most of the radioactivity was eliminated in the faeces. Approximately 2% of the radioactivity was eliminated in the urine. Less than 1% of unchanged tacrolimus was detected in the urine and faeces, indicating that tacrolimus is almost completely metabolised prior to elimination: bile being the principal route of elimination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The kidneys and the pancreas were the primary organs affected in toxicity studies performed in rats and baboons. In rats, tacrolimus caused toxic effects to the nervous system and the eyes. Reversible cardiotoxic effects were observed in rabbits following intravenous administration of tacrolimus. When tacrolimus is administered intravenously as rapid infusion/bolus injection at a dose of 0.1 to 1.0 mg/kg, QTc prolongation has been observed in some animal species. Peak blood concentrations achieved with these doses were above 150 ng/mL which is more than 6-fold higher than mean peak concentrations observed with CROTAL in clinical transplantation.</p><p>Embryofoetal toxicity was observed in rats and rabbits and was limited to doses that caused significant toxicity in maternal animals. In rats, female reproductive function including birth was impaired at toxic dosages and the offspring showed reduced birth weights, viability and growth.</p><p>A negative effect of tacrolimus on male fertility in the form of reduced sperm counts and motility was observed in rats.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:555px"><tbody><tr><td><p><strong>Name of Ingredients</strong></p></td><td style="vertical-align:top"><p><strong>0.5 mg</strong></p><p><strong>Unit Dose</strong></p><p><strong>(mg)</strong></p></td><td><p><strong>1mg</strong></p><p><strong>Unit Dose</strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:top"><p><strong>5mg</strong></p><p><strong>Unit Dose</strong></p><p><strong>(mg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Tacrolimus PreMix</p></td><td style="vertical-align:top"><p>2.50</p></td><td><p>5.000</p></td><td><p>25.000</p></td></tr><tr><td style="vertical-align:bottom"><p>Lactose monohydrate NF</p><p>(Pharmatose DCL-11)</p></td><td style="vertical-align:top"><p>100.00</p></td><td><p>97.500</p></td><td><p>77.500</p></td></tr><tr><td style="vertical-align:bottom"><p>Lactose monohydrate NF</p><p>(Impalpable)</p></td><td style="vertical-align:top"><p>34.00</p></td><td><p>34.000</p></td><td><p>34.000</p></td></tr><tr><td style="vertical-align:bottom"><p>Croscarmellose Sodium NF</p></td><td style="vertical-align:top"><p>2.00</p></td><td><p>2.000</p></td><td><p>2.000</p></td></tr><tr><td style="vertical-align:bottom"><p>Magnesium Stearate NF</p></td><td style="vertical-align:top"><p>1.50</p></td><td><p>1.500</p></td><td><p>1.500</p></td></tr><tr><td style="vertical-align:top"><p>Size &quot;4&quot; empty hard gelatin capsule shell.</p></td><td style="vertical-align:top"><p>With dark yellow opaque cap imprinted with &ldquo;0.5 MG&rdquo; and dark yellow opaque body imprinted with &ldquo;RDY 525&rdquo; using red ink.</p></td><td style="vertical-align:top"><p>With white opaque cap imprinted with &quot;1MG&quot; and white opaque body imprinted with &quot;RDY 526&quot; using red ink</p></td><td style="vertical-align:top"><p>With dark greyish red opaque cap imprinted with &quot;5MG&quot; and dark greyish red opaque body imprinted with &quot;RDY 527&quot; using white ink.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24Months/2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Blister</strong>: 10 capsules per each blister.</p><p>All strength contains 100 Capsules/10 Blisters/UNCTN</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by 
Dr. Reddy's Laboratories Limited
FOR
SPIMACO

Al-Qassim pharmaceutical plant


Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2019.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>